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Summary Therapeutic angiogenesis is an important means for salvaging tis-
sues from severe ischemic diseases in patients with no option for other vascular
interventions. A number of recent studies examined the possibilities of cell
transplantation-mediated angiogenesis using autologous bone marrow mononuclear
cells, CD34+ cells, peripheral mononuclear cells, etc. Subcutaneous adipose tissue
can be harvested by relatively easy technology. Recent studies indicate that adi-
pose tissue contains progenitor cells that can give rise to several mesenchymal
lineages. Moreover, these progenitor cells can release multiple angiogenic growth
factors including vascular endothelial growth factor, hypatocyte growth factor, and
chemokine stromal cell-derived factor. The combination of these biological proper-
ties of adipose-derived regenerative cells indicates that autologous adipose tissue
will be a useful cell source for therapeutic angiogenesis.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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Introduction
When tissue is exposed to severe ischemia, new
blood vessels develop into the ischemic tissues to
prevent further damage and eventual necrosis [1].
However, this endogenous protective mechanism
(i.e. angiogenesis and/or collateral vessel forma-
tion) is often hampered by co-existing morbidity
and atherosclerotic risk factors. For example,
diabetic patients frequently lose their lower
extremities after suffering from peripheral artery
obstructive disease (PAOD) because of insufﬁcient
development of collateral vessels. Therefore, a
strategy termed ‘‘therapeutic angiogenesis’’ is an
important means to salvage tissues against severe
ischemic diseases [1].
Subcutaneous adipose tissue can be harvested by
minimal invasive technology. Furthermore, recent
studies have indicated that adipose tissue contains
progenitor cells that can give rise to several lin-
eages including fat, bone, cartilage, muscle, etc.
[2,3]. These progenitor cells have been recently
termed as adipose-derived stem/progenitor cells
(ASCs or ADSCs), or adipose-derived regenerative
cells (ADRCs), and these terminologies including
adipose-derived stromal vascular fraction (SVF)
are essentially considered as an identical cell
fraction. ADSCs/ADRCs can also release multiple
angiogenesis-related growth factors including vas-
cular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF), and chemokine stromal cell-
derived factor-1 (SDF-1) [4—6]. The combination
of these biological properties (i.e. progenitor cell
supply and growth factor release) suggests that
autologous subcutaneous adipose tissue will be a
next generation candidate for the cell source of
therapeutic angiogenesis [4—11] (Table 1).
Therapeutic angiogenesis—–growth
factor gene and cytokine therapy
Judah Folkman, one of the pioneers of angiogene-
sis research, initiated the concept of therapeutic
angiogenesis in the early 1970s [12,13]. Folkman
observed that pathological neovascularization is
essential for the growth and metastasis of solid
tumors. His original idea that the suppression of
tumor angiogenesis would be effective against
tumor growth has now developed into a completely
new paradigm of anti-angiogenic therapy against
neoplastic diseases [13].
After the identiﬁcation of angiogenic growth fac-
tors including VEGF and basic ﬁbroblast growth
factor (bFGF), investigators in the cardiovascu- T
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ar ﬁeld started testing their hypothesis that
acilitating angiogenesis with growth factor genes
nd/or cytokines would improve tissue perfusion
nd function in severe ischemic diseases [14—16].
number of preclinical data supported the safety
nd feasibility of clinical application of therapeutic
ngiogenesis using growth factor genes or proteins.
hereafter, abundant clinical trials have been per-
ormed to conduct therapeutic angiogenesis with
enes and cytokines [17]. Initial uncontrolled small
linical trials showed successful results, however,
ore recent larger clinical studies with random-
zed placebo-controlled trials often failed to show
ufﬁcient improvement of angiogenesis, function,
r symptoms [17]. These ﬁndings suggest that the
linical use of therapeutic angiogenesis using sin-
le factors may have limited efﬁcacy. This could
ell be explained by the fact that the expression
f more than 750 genes was either up-regulated
r down-regulated >2-fold by acute ischemic insult
n vivo [18], and such dramatic changes may not
asily be restored by cytokine monotherapy. So far,
nly a small number of studies using HGF or bFGF
ave shown to reveal promising data, but this may
e because a number of cytokines or transcription
actors are expressed downstream to this cytokine-
ediated signal transduction [19—21].
herapeutic angiogenesis—–cell therapy
eantime, a pioneering work conducted by Asa-
ara et al. regarding the identiﬁcation of putative
ndothelial progenitor cells (EPCs) in adult human
eripheral blood was published in 1997 [22]. Since
PCs and hematopoietic stem cells (HSCs) share
everal cell surface antigens such as Flk-1, Tie-2,
D31, and CD34, EPCs are believed to derive from
o-called hemangioblasts or a closely related cell
lass existing in the bone marrow in adulthood [23].
obilized EPCs circulate in the peripheral blood and
articipate in new blood vessel formation and re-
ndothelialization on the injured arterial inner wall
22]. Although transplantation of culture expanded
PCs could successfully augment angiogenesis and
issue blood supply in experimental animal mod-
ls with ischemia [24], this procedure has not been
eveloped into clinical trials because of difﬁculties
n culture expansion techniques and limited number
f cells to implant.
Instead, based on the idea that patients’ ownone marrow can be obtained relatively easily
nd that fresh bone marrow contains HSCs and
PCs [23], implantation of autologous bone marrow
ononuclear cells has been investigated in both
reclinical and clinical studies [25—28]. Adult bone
h
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arrow has been shown to contain EPCs that mobi-
ize into peripheral circulation after stimulation by
schemia or by cytokines such as VEGF and SDF-1
29—31]. We previously demonstrated that implan-
ation of autologous bone marrow mononuclear
ells into ischemic skeletal muscles successfully
ugmented angiogenesis and collateral vessel for-
ation in both animal studies and human trials
25,26,28,32]. Especially in the clinical study called
‘TACT trial,’’ we have shown that more than 80% of
uerger’s disease patients and 50% of PAOD patients
ere responsive to this new therapeutic modality
33,34].
However, there are several limiting factors for
his procedure. One is that the procedure itself
s sometime too invasive for patients with critical
imb ischemia or endstage ischemic heart disease.
n the TACT protocol, approximately 1—3× 109
one marrow mononuclear cells were required
or cell transplantation therapy in limb ischemia
atients, which contains 1—3× 107 CD34+ cells and
eeds about ∼800mL of fresh bone marrow aspi-
ated from the ileum [34]. Moreover, for this entire
rotocol, patients must be under general anesthe-
ia. Secondly, the mechanism of angiogenesis by
one marrow mononuclear cell implantation had
een studied by several investigators, and these
tudies suggested that differentiation of bone mar-
ow mononuclear cells into endothelial cells was
arely seen within the implanted skeletal mus-
le tissues. However, cytokines and chemokines
eleased from implanted mononuclear cells would
timulate pre-existing endothelial cells to sprout
ia either a direct or indirect manner. Kamihata
t al. showed that cytokines such as VEGF and
FGF released from implanted marrow mononu-
lear cells were likely main players for angiogenesis
y stimulating ‘‘resident’’ endothelial cells [26].
omuro and co-workers showed that inﬂammatory
ytokine IL-1 released from implanted mononuclear
ells stimulates immature skeletal myocytes cells
o release VEGF that then stimulated the angiogenic
prout of resident endothelial cells [35]. Thus,
here is now skepticism about the initially pre-
ented direct differentiation mechanism of marrow
ononuclear cells into mature endothelial cells.
hirdly, although the safety and efﬁciency of the
ACT protocol have been established, we recently
eported that patients with severe endstage PAOD
ad poor responses to the TACT procedure [32].
or example, patients with diabetes or chronic
emodialysis due to end stage renal disease (ESRD)
howed poor responses to the TACT procedure [32].
oreover, recent studies indicated that patients
ith severe PAOD, ischemic heart disease, and/or
ultiple coronary risk factors had diminished func-
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tions of EPCs and poor responses to angiogenic
cell therapy [36—39]. This suggests that even if
fresh autologous marrow mononuclear cells were
isolated, the function of stem/progenitor cells per
se is already reduced and is too weak to induce
sufﬁcient angiogenesis after implantation into the
‘‘host’’ ischemic tissues [36]. It has been demon-
strated that the efﬁcacy of the TACT procedure was
limited in patients with poorly controlled diabetes
and ESRD [32]. In such patients, the number and
functions of EPCs are also reduced and are difﬁcult
to isolate. Also, we previously demonstrated that
the number and function of circulating EPCs were
markedly reduced in chronic smokers even without
other risk factors [40]. This reduction was persis-
tent and was not easily restored by treatment with
a HMG-CoA reductase inhibitors (statins) that have
been shown to stimulate mobilization of EPCs from
bone marrow [41,42].
Alternative cell source for therapeutic
angiogenesis
Since bone marrow aspiration is relatively inva-
sive for patients with severe ischemic diseases, less
invasive techniques for isolating cells for angio-
genic therapy have been warranted. One of the
most attractive sources for isolating cells for ther-
apeutic angiogenesis would be human umbilical
cord/placental blood. Before the founding of cord
blood banks, cord blood was totally abandoned
and not considered for any therapeutic application.
However, cord blood had been shown to contain
a substantial number of hematopoietic colony-
forming cells [43], and in 1989 there appeared
the ﬁrst clinical report regarding transplantation of
cord blood for patients with a hematological disor-
der [44]. In contrast to adult bone marrow-derived
hematopoietic stem cells, cord blood progenitors
have proliferative advantages, including the capac-
ity to form a greater number of colonies, a higher
cell-cycle rate, and longer telomere length [45,46].
Moreover, the immaturity of T-lymphocytes in cord
blood may reduce the risk and severity of graft-
versus-host diseases (GVHDs) [47]. All of these
properties should favor the engraftment and growth
of the cord blood progenitors being used for thera-
peutic angiogenesis.
In 1997, Nieda et al. ﬁrst reported that EPCs
are normal components of human umbilical cord
blood [48]. Thereafter, we were able to demon-
strate that human cord blood mononuclear cells
could give rise to EPCs by in vitro cultivation
methods [49] similar to those reported by Asa-
c
e
m
g
ET. Murohara
ara et al. [22]. Moreover, implantation of human
ord blood-derived EPCs signiﬁcantly augmented
ngiogenesis in ischemic hind limb of immunode-
cient nude rats [49]. More recently Kim et al.
emonstrated in a preliminary clinical trial that
mplantation of human cord blood-derived mes-
nchymal stem cells enhanced angiogenesis and
ollateral vessel formation in human cases with
uerger’s disease [50]. However, there are still
ritical ethical issues including potential GVHDs
o be resolved before the clinical application
f this technique for vascular disorders because
mmunosuppressants are normally not used for such
atients.
dipose-derived stem/progenitor cells
r regenerative cells
nother interesting cell source for therapeutic
ngiogenesis is autologous subcutaneous adipose
issue (Table 1). Adipose tissue mainly comprises
wo classes of cells. One is mature adipocytes
MAs) forming the major part of adipose tissue
olume, and the other is stromal cells termed
tromal vascular fraction (SVF). Several studies
ave demonstrated that SVF contains multi-potent
esenchymal stem/progenitor cells that could
ifferentiate into various lineages including ﬁbrob-
asts, adipocytes, pericytes, osteoblasts, chondro-
ytes, and myocytes [2,3]. Recently, it has been
eported that adipose tissues contain multipotent
esenchymal stem cells termed adipose-derived
tem/progenitor cells (ASCs or ADSCs) or adipose-
erived regenerative cells (ADRCs) that have an
bility to regenerate damaged tissues. ADRCs could
e isolated from even a small amount of human
ubcutaneous adipose tissues and are culture-
xpandable (Fig. 1) [3]. Therefore, autologous
DRCs could be isolated with minimal invasiveness
51].
herapeutic angiogenesis using
dipose-derived regenerative cells—–a
ew paradigm
lthough some studies reported that adipose-
erived cells could be able to differentiate into
Cs or EPCs [7,8,10], in our recent investigation we
ould not conﬁrm that ADRCs differentiate into the
ndothelial lineage [6]. One study used low-serum
edium supplemented with VEGF and insulin-like
rowth factor-1 (IGF-1) to direct ADRCs to ECs or
PCs [7]. The difference of such culture conditions
Adipose-derived regenerative cells and angiogenesis 159
Figure 1 (A) Characterization of cultured ADRCs. Phase contrast micrographs of adherent ADRCs 24 h (a) and 1
week (b) after plating (100×). (c) Phase contrast micrograph of adipogenic differentiated ADRCs including lipid-ﬁlled
droplets (400×). (d) Adipogenic differentiated ADRCs stained with Oil Red O (400×). (e) ADRCs were stained with
anti--SMA antibody conjugated with Alexa 594 (red), counterstained with DAPI (100×). (f and g) Endothelial
differentiation was not conﬁrmed by immunostaining with anti-PECAM mAb conjugated with Alexa 488 or by
DiI-Ac-LDL incorporation and FITC-BS1 lectin binding. (B) Flow cytometry analysis of cultured ADRCs (P2). R3 area
shows respective isotype control for each antibody, and R4 area depicts positive signals for each antibody. ADRCs
were positive for Sca-1, but not for CD34, c-kit, CD31, ﬂk-1, nor Lin.
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might have affected the differentiation pattern of
ADRCs into ECs or other lineages [52]. Nevertheless,
a recent study failed to show that human ADRCs
differentiated into ECs even under culture with
endothelial speciﬁc medium EGM-2 [53]. In addi-
tion, we could not conﬁrm differentiation of ADRCs
into ECs in vivo. Implanted GFP-positive ADRCs
expressed no endothelial marker, but implanted
ADRCs were positive for CD140b, also known
as PDGF receptor B and a myoﬁbroblast-speciﬁc
marker, and co-localized with vessels like pericytes
[6]. These results suggest that ADRCs might not
have the capability to differentiate into EPCs or
mature ECs but smooth muscle lineage cells. Sim-
ilarly, several recent studies showed that ADRCs
differentiated into pericytes in vitro and in vivo
[53—55].
Although our study and previous studies failed to
show the differentiation of ADRCs or ASCs into EC
lineage, it has been shown that ADRCs can secrete
multiple angiogenic growth factors or cytokines
such as VEGF and HGF [4,5]. Thus, it seems that
autologous adipose tissue-derived cells may be
useful for therapeutic angiogenesis via a growth
factor-dependent manner. Nakagami et al. and
Sumi et al. reported that implanation of adipose-
derived mesenchymal cells did induce angiogenesis
via secretion of angiogenic growth factors [5,10].
We also found that implantation of ADRCs signiﬁ-
cantly augmented angiogenesis in a mouse model
of hind limb ischemia [6]. Our data indicated that
implantation of ADRCs induced angiogenesis not
by an endothelial differentiation of ADRCs but
by chemokines such as SDF-1 [6]. Interestingly,
we found that implantation of MAs into skeletal
muscles even worsened angiogenesis compared to
saline-injected control mice. We found that ADRCs
expressed SDF-1, and the abundance of mRNA and
protein expression were signiﬁcantly greater in
ADRCs than in MAs [6]. Recent studies indicated
that MAs release other adipocytokines including
tumor necrosis factor- and interleukin-6. These
deleterious inﬂammatory cytokines might have neg-
atively affected angiogenesis by MA implantation
observed in our recent study [6]. SDF-1 is a member
of CXC chemokines originally isolated from murine
BM stromal cells [56]. CXCR4 is the receptor for
SDF-1 and is a co-receptor for human immunode-
ﬁciency virus type 1 infection [57]. SDF-1/CXCR4
interaction regulates multiple physiological pro-
cesses including embryonic development and organ
homeostasis. Interestingly, SDF-1 is considered as
one of the key regulators of EPCs trafﬁcking from
BM into PB as well [31]. Thus, SDF-1 has been
shown to augment neovascularization by accelera-
tion of EPC recruitment into ischemic foci [31,58].
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n addition, VEGF is one of the powerful angio-
enic cytokines that can also mobilize EPCs from
M and inhibit EPC apoptosis [59]. Interestingly,
n the mouse ischemic hind limb model, VEGF-
-mediated angiogenesis partly depends on the
ctivation of the SDF-1—CXCR4 pathway [58]. Taken
ogether, chemokine SDF-1 likely plays a pivotal
ole for ADRC-mediated angiogenesis [6]. In fact,
herapeutic efﬁcacy and mobilization of EPCs of
DRC implantation was markedly suppressed by
njection of an anti-SDF-1 neutralizing mAb in our
tudy [6].
DRC therapy for
ngiogenesis—–unanswered questions
nd perspectives
lthough the efﬁcacy of autologous ADRC implan-
ation for therapeutic angiogenesis has been
stablished in animal studies, it is still unknown
ow many cells should be used for optimal angio-
enesis. In the case of marrow mononuclear
ells, it has been reported that the injection of
oo many cells resulted in adverse effects in an
nimal model [60]. It is necessary to determine
he optimum dosage of ADRC implantation. The
econd question is what is the optimal cell isolation
ethod? Recently, freshly isolated ADRCs by means
f collagenase digestion followed by an automatic
entrifuge system using a speciﬁc machine has
een shown to be useful for regeneration of adipose
issues for reconstructive surgeries [51,61]. Such a
echnique does not need a cell culture system and
hus does not require an established cell processing
enter (CPC). If two classes of ADRCs obtained by
ither culture method or fresh isolation method
ave equal potency in terms of releasing angiogenic
rowth factors, it will be useful to employ such a
achine for cell-mediated therapeutic angiogene-
is. Thirdly, either ADRC number or functions may
e affected by patients’ concomitant conditions
r atherogenic risk factors. For example, SDF-1
ecretion is reduced in type 2 diabetes [62],
nd the function and number of progenitors are
enerally reduced in patients with multiple risk
actors including diabetes, hypertension, aging,
nd smoking [37—40]. Such pathological condi-
ions are commonly complicated in patients with
AOD and/or Buerger’s disease. It is still unknown
hether ADRC number and functions are inﬂuenced
y the presence of such risk factors as well. Before
pplying this new technique to therapeutic angio-
enesis, it will be necessary to elucidate these
oints.
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